Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

The current public-health risk is low, but the CDC is working with states to monitor people with animal exposure.

The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

The biotech company said it anticipates between $1.5 billion and $2.5 billion in revenue this year, below Wall Street ...

Moderna Inc. entered the new year on the heels ... “(If I) tell you there’s this new biotech company…that has $2 billion of sales, two products approved, $9 billion in the bank, just filed ...

Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance.

Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...

SAN FRANCISCO, Jan. 13, 2025 /PRNewswire/ -- Kerna Laboratories Inc, a San Francisco-based AI biotech startup, emerged from stealth with the launch of an AI platform for developing novel RNA-based ...